Skip to main content
Gareth Morgan, MD, Hematology, New York, NY, NYU Langone Hospitals

GarethMorganMDPhD, FRCP, FRCPath

Hematology • New York, NY

Hematologic Oncology

Professor Medicine and Director Myeloma Research

Join to view full profile

Dr. Morgan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Morgan's full profile

Already have an account?

Summary

  • Dr Morgan is a recognized international expert and thought leader on multiple myeloma and its treatment. He has been a major force translating genetic advances from the laboratory to the clinic to improve patient care. He has received peer-reviewed project and programme funding for the last 25 years. Within the laboratory his initial work concentrated on chronic myeloid leukaemia (CML) and paediatric acute lymphoblastic leukemia (ALL) where he was involved in the molecular characterisation of the Philadelphia chromosome and was the first person to apply sensitive DNA and RNA based PCR for the detection of minimal residual disease (MRD) in CML; and in paediatric ALL where he published the first molecular characterisation of the t(11;19). These interests in both MRD and how transcription factor abnormalities and epigenetic change act as drivers of cancer progression now continue in multiple myeloma, as he believes this disease provides an excellent model system of cancer progression with which to study such events. Utilizing large patient sample sets from clinical trials on which he has been a principle investigator, he has published extensively on treatment advances and the genetics of myeloma initially utilising FISH, SNP arrays and more recently WES and WGS, and identified the importance of evolutionary biology in myeloma progression. To study the role played by the cells of the bone marrow microenvironment he has explored de-convolution algorithms, applicable to RNA extracted from whole bone marrow biopsies, and more recently utilized high-throughput flow cytometry and single cell technologies to further define these cells. Using 10X WGS he has also defined missing driver variants and characterized complex structural chromosomal rearrangements and determined their prognostic significance.

Education & Training

  • The University of Wales College of Medicine
    The University of Wales College of MedicineClass of 1981, MB BCh
  • University of London
    University of LondonPhD, Genetics of Leukemia

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2020 - 2025
  • AR State Medical License
    AR State Medical License 2014 - 2019
  • FRCPFellow Royal College Physicians
  • FRCPathFellow of the Royal College of pathologists

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Perlmutter Cancer Center Appoints Inaugural Director of Center for Blood Cancers
    Perlmutter Cancer Center Appoints Inaugural Director of Center for Blood CancersJanuary 24th, 2022
  • The Hospital Is Overwhelmed by COVID New Orleans CEO Florida Louisiana Arkansas and Has a Shortage of Nurses
    The Hospital Is Overwhelmed by COVID New Orleans CEO Florida Louisiana Arkansas and Has a Shortage of NursesAugust 10th, 2021

Grant Support

  • Mutographs in myelomaNCI2021–2026
  • Myeloma Translational ResearchAmmon Foundation2020–2025
  • Structural Variation in Multiple MyelomaLeukemia Lymphoma Society2020–2023
  • Smoldering Multiple MyelomaMMRF2019–2021

Research History

  • Director Myeloma ResearchAppointed as Director of Myeloma Research at NYU2019 - Present

Hospital Affiliations

Dr. Gareth Morgan, Dr. Gareth Morgan, MD, Dr. G Morgan